Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 9/20 | 0.50 |
| ▸ | CTSK | P43235 | 5/20 | 0.50 |
| ▸ | CTSS | P25774 | 5/20 | 0.50 |
| ▸ | CTSH | P09668 | 4/20 | 0.50 |
| ▸ | CTSL | P07711 | 4/20 | 0.50 |
| ▸ | CTSF | Q9UBX1 | 2/20 | 0.50 |
| ▸ | CTSV | O60911 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25658847 | 0.81 | CTSB (0.50) | CTSBCTSKCTSSCTSHCTSL | |
| SCHEMBL25658807 | 0.81 | CTSB (0.50) | CTSBCTSKCTSSCTSHCTSL | |
| SCHEMBL19982934 | 0.75 | CTSB (0.51) | CTSBCTSKCTSSCTSHCTSL | |
| SCHEMBL25658790 | 0.75 | CTSB (0.51) | CTSBCTSKCTSSCTSHCTSL | |
| SCHEMBL19982937 | 0.75 | CTSB (0.51) | CTSBCTSKCTSSCTSHCTSL | |
| SCHEMBL19982936 | 0.75 | CTSB (0.51) | CTSBCTSKCTSSCTSHCTSL | |
| SCHEMBL19982935 | 0.75 | CTSB (0.51) | CTSBCTSKCTSSCTSHCTSL | |
| SCHEMBL25658832 | 0.75 | CTSB (0.51) | CTSBCTSKCTSSCTSHCTSL | |
| SCHEMBL19982981 | 0.72 | CTSK (0.52) | CTSBCTSKCTSSCTSHCTSL | |
| SCHEMBL19972771 | 0.72 | CTSK (0.55) | CTSBCTSKCTSSCTSHCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142714-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142714-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | CTSB 282/4885CTSK 379/4885CTSS 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.